Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
44
SLDB Quote, Financials, Valuation and Earnings
Last price:
$5.92
Seasonality move
:
29.17%
Day range:
$5.36 - $5.97
52-week range:
$2.41 - $7.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
20.36x
P/B ratio:
1.86x
Volume:
712.7K
Avg. volume:
1.2M
1-year change:
14.29%
Market cap:
$404.4M
Revenue:
--
EPS (TTM):
-$2.49
Analysts' Opinion
-
Consensus RatingSolid Biosciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.17, Solid Biosciences, Inc. has an estimated upside of 192.23% from its current price of $5.92.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.00 representing 100% downside risk from its current price of $5.92.
Fair Value
-
According to the consensus of 9 analysts, Solid Biosciences, Inc. has 192.23% upside to fair value with a price target of $15.17 per share.
SLDB vs. S&P 500
-
Over the past 5 trading days, Solid Biosciences, Inc. has overperformed the S&P 500 by 0.77% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Solid Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Solid Biosciences, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Solid Biosciences, Inc. reported revenues of --.
Earnings Growth
-
Solid Biosciences, Inc. has grown year-over-year earnings for 7 quarters straight. In the most recent quarter Solid Biosciences, Inc. reported earnings per share of -$0.48.
Enterprise value:
190.1M
EV / Invested capital:
0.79x
Price / LTM sales:
20.36x
EV / EBIT:
--
EV / Revenue:
12.22x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.43x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.7M
Return On Assets:
-62.99%
Net Income Margin (TTM):
--
Return On Equity:
-77.74%
Return On Invested Capital:
-70.08%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$2.9M | -$2.6M | -$1.7M | -$405K | -$376K | |
| Operating Income | -$111M | -$112.1M | -$169.7M | -$35.2M | -$48.1M | |
| EBITDA | -$108.1M | -$109.5M | -$168M | -$34.8M | -$47.7M | |
| Diluted EPS | -$4.61 | -$3.04 | -$2.49 | -$0.79 | -$0.48 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $238.8M | $147.5M | $148.3M | $179.5M | $244.9M | |
| Total Assets | $249M | $184.5M | $184.7M | $211.8M | $273.9M | |
| Current Liabilities | $22.5M | $16.9M | $15.8M | $22.9M | $36.3M | |
| Total Liabilities | $25.6M | $41.2M | $40.4M | $44.8M | $56M | |
| Total Equity | $223.4M | $143.3M | $144.4M | $167M | $217.9M | |
| Total Debt | $2.3M | $24.6M | $25M | $23M | $19.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$107.8M | -$91.2M | -$132.4M | -$23.7M | -$33.5M | |
| Cash From Investing | $30.5M | -$9.4M | -$66.9M | -$11M | -$45.3M | |
| Cash From Financing | $77.4M | $116M | $196.2M | $3.3M | $1.2M | |
| Free Cash Flow | -$110.1M | -$91.7M | -$133.2M | -$23.7M | -$33.6M | |
SLDB
Sector
Market Cap
$404.4M
$28.4M
Price % of 52-Week High
70.42%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-39.69%
-1.32%
1-Year Price Total Return
0.19%
-22.19%
Beta (5-Year)
2.975
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$5.28
200-day SMA
Buy
Level
$4.90
Bollinger Bands (100)
Buy
Level
4.94 - 6.38
Chaikin Money Flow
Sell
Level
-83.1M
20-day SMA
Buy
Level
$4.75
Relative Strength Index (RSI14)
Buy
Level
64.56
ADX Line
Buy
Level
15.57
Williams %R
Neutral
Level
-20.0772
50-day SMA
Buy
Level
$5.35
MACD (12, 26)
Buy
Level
0.08
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Neutral
Level
122.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.3858)
Sell
CA Score
(Annual)
Level (-2.645)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (4.9239)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.
Stock Forecast FAQ
In the current month, SLDB has received 9 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SLDB average analyst price target in the past 3 months is $15.17.
-
Where Will Solid Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Solid Biosciences, Inc. share price will rise to $15.17 per share over the next 12 months.
-
What Do Analysts Say About Solid Biosciences, Inc.?
Analysts are divided on their view about Solid Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Solid Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $9.00.
-
What Is Solid Biosciences, Inc.'s Price Target?
The price target for Solid Biosciences, Inc. over the next 1-year time period is forecast to be $15.17 according to 9 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SLDB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Solid Biosciences, Inc. is a Buy. 9 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SLDB?
You can purchase shares of Solid Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Solid Biosciences, Inc. shares.
-
What Is The Solid Biosciences, Inc. Share Price Today?
Solid Biosciences, Inc. was last trading at $5.92 per share. This represents the most recent stock quote for Solid Biosciences, Inc.. Yesterday, Solid Biosciences, Inc. closed at $5.92 per share.
-
How To Buy Solid Biosciences, Inc. Stock Online?
In order to purchase Solid Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SLDB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SLDB
Sector
P/E ratio
--
23.66x
PEG ratio
--
-0.01x
P/B ratio
1.86x
1.84x
Price / LTM sales
20.36x
1.60x
Growth Metrics
SLDB
Sector
Revenue growth
--
4.85%
Earnings growth
38.6%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.44
-$0.20
Profitability
SLDB
Sector
Profitability FY 2024
-$2.5M
$3.6M
Return on invested capital
-70.08%
-30.98%
Return on assets
-62.99%
-27.62%
Return on equity
-77.74%
-36.69%
Earnings Date
Last Earnings Date
Nov
3
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
2
Balance Sheet
SLDB
Sector
Total cash
$236.1M
$27.2M
Short term investments
$68.7M
$25.7M
Total assets
$188.7M
$79.9M
Long term debt
$19.9M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
38
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
